Table 1 Demographics and clinical characteristics of patients
Variable | N=19 (%)/[range] | P value |
|---|---|---|
Gender | Â | 0.326 |
 Female | 12 (63.2) | |
 Male | 7 (36.8 | |
Age, median | 58 [34–70] |  |
ECOG status | Â | 0.617 |
 0 | 13 (68.4) | |
 1 | 6 (31.6) | |
Histopathology (biopsy) | Â | 0.368 |
 Adenocarcinoma | 18 (94.7) | |
 Squamous cell carcinoma | 1 (5.3) | |
Genetic mutation | Â | 0.282 |
 EGFR | 16 (84.2) | |
 ALK | 2 (10.5) | |
 Nil | 1 (5.3) | |
Clinical stage at diagnosis | Â | 0.617 |
 IIIA/IIIB | 4/2 (31.6) | |
 IVA/IVB | 12/1 (68.4) | |
Preoperative staging after TKI | Â | 0.154 |
 IA | 2 (10.5) | |
 IIA/IIB | 2/2 (21.1) | |
 IIIA | 13 (68.4) | |
ypStage | Â | 0.352 |
 IA/IB | 4/3 (36.8) | |
 IIB | 2 (10.5) | |
 IIIA/IIIB | 7/1 (42.1) | |
 IVA | 2 (10.5) | |
Type of preoperative TKI | Â | 0.091 |
 Afatinib | 7 (36.8) | |
 Gefitinib | 6 (31.6) | |
 Erlotinib | 3 (15.8) | |
 Osimertinib | 1 (5.3) | |
 Alectinib | 1 (5.3) | |
 Crizotinib | 1 (5.3) | |
Median duration of preoperative TKI, months | 5 [0.8–66] | 0.611 |
 Neoadjuvant | 2.5 [1.5-6] | |
 Treatment | 5.8 [0.8-66] | |
Indication for preoperative TKI | Â | 1.000 |
 Neoadjuvant | 5 (26.3) | |
 Treatment | 14 (73.7) | |
Indication for surgery | Â | 0.123 |
 Regressed disease | 17 (89.5) | |
 Regrowth disease | 2 (10.5) | |
Duration of follow-up, median months | 22 [1–85] |  |